These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36882925)

  • 21. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
    Seephetdee C; Bhukhai K; Buasri N; Leelukkanaveera P; Lerdwattanasombat P; Manopwisedjaroen S; Phueakphud N; Kuhaudomlarp S; Olmedillas E; Saphire EO; Thitithanyanont A; Hongeng S; Wongtrakoongate P
    Antiviral Res; 2022 Aug; 204():105370. PubMed ID: 35772601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
    Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern.
    Rudi E; Martin Aispuro P; Zurita E; Gonzalez Lopez Ledesma MM; Bottero D; Malito J; Gabrielli M; Gaillard E; Stuible M; Durocher Y; Gamarnik AV; Wigdorovitz A; Hozbor D
    Front Immunol; 2022; 13():1020159. PubMed ID: 36248791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
    González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
    Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.
    Wang R; Huang H; Yu C; Sun C; Ma J; Kong D; Lin Y; Zhao D; Zhou S; Lu J; Cao S; Zhang Y; Luo C; Li X; Wang Y; Xie L
    Sci China Life Sci; 2023 Aug; 66(8):1818-1830. PubMed ID: 36598621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
    Chen WH; Tao X; Agrawal AS; Algaissi A; Peng BH; Pollet J; Strych U; Bottazzi ME; Hotez PJ; Lustigman S; Du L; Jiang S; Tseng CK
    Vaccine; 2020 Nov; 38(47):7533-7541. PubMed ID: 33039209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern.
    Lee IJ; Lan YH; Wu PY; Wu YW; Chen YH; Tseng SC; Kuo TJ; Sun CP; Jan JT; Ma HH; Liao CC; Liang JJ; Ko HY; Chang CS; Liu WC; Ko YA; Chen YH; Sie ZL; Tsung SI; Lin YL; Wang IH; Tao MH
    Emerg Microbes Infect; 2023 Dec; 12(1):2149353. PubMed ID: 36395071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2.
    Meena J; Singhvi P; Srichandan S; Dandotiya J; Verma J; Singh M; Ahuja R; Panwar N; Wani TQ; Khatri R; Siddiqui G; Gupta A; Samal S; Panda AK
    Eur J Pharm Biopharm; 2022 Jul; 176():43-53. PubMed ID: 35589003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
    Liu D; An C; Bai Y; Li K; Liu J; Wang Q; He Q; Song Z; Zhang J; Song L; Cui B; Mao Q; Jiang W; Liang Z
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants.
    Mi T; Wang T; Xu H; Sun P; Hou X; Zhang X; Ke Q; Liu J; Hu S; Wu J; Liu B
    Virology; 2022 Apr; 569():56-63. PubMed ID: 35276485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of humoral immune responses induced by different SARS-CoV-2 spike trimers from wild-type and emerging variants with individual, sequential, and combinational delivered strategies.
    Ding C; Ni S; Zhang X; Xie J; Sun Y; He J; Mei Q; Huang L; He H; Liu Z; Gao Y
    J Med Virol; 2022 Dec; 94(12):5841-5849. PubMed ID: 35986565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
    Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
    Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins.
    Chen J; Xu W; Li L; Yi L; Jiang Y; Hao P; Xu Z; Zou W; Li P; Gao Z; Tian M; Jin N; Ren L; Li C
    Front Cell Infect Microbiol; 2022; 12():967493. PubMed ID: 35923799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
    Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
    Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
    Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.